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Summary
Objective: Alternative medicine is used extensively by patients with chronic pain due to e.g., osteoarthritis. Only few of these drugs have be
tested in a controlled setting and the present study was undertaken to examine the effect of ginger extract, one of the most popular herbal
medications.
Design: Ginger extract was compared to placebo and Ibuprofen in patients with osteoarthritis of the hip or knee in a controlled, double blind,
double dummy, cross-over study with a wash-out period of one week followed by three treatment periods in a randomized sequence, each
of three weeks duration. Acetaminophen was used as rescue medication throughout the study. The study was conducted in accordance with
Good Clinical Practice (European Guideline for GCP).
Results: A ranking of efficacy of the three treatment periods: Ibuprofen>ginger extract>placebo was found for visual analogue scale of pain
(Friedman test: 24.65, P<0.00001) and the Lequesne-index (Friedman test: 20.76, P<0.00005). In the cross-over study, no significant
difference between placebo and ginger extract could be demonstrated (Siegel-Castellan test), while explorative tests of differences in the first
treatment period showed a better effect of both Ibuprofen and ginger extract than placebo (Chi-square, P<0.05). There were no serious
adverse events reported during the periods with active medications.
Conclusion: In the present study a statistically significant effect of ginger extract could only be demonstrated by explorative statistical
methods in the first period of treatment before cross-over, while a significant difference was not observed in the study as a whole. © 2000
OsteoArthritis Research Society International
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Patients with chronic, painful diseases often seek
alternative therapy,1 and currently, ginger is one of the
most popular herbal medications for rheumatic diseases.
Beneficial effects of ginger have been reported casuisti-
cally,2 while no controlled study of the effect has been
performed previously. Acetaminophen is generally advo-
cated as a pain killer in osteoarthritis, however, many
patients use NSAIDs for prolonged periods with the haz-
ards this may imply due to serious gastric adverse
events. The present study was undertaken to test ginger
extracts as an alternative to the NSAID as supplementary
drug.
With acetaminophen as basal therapy, a three group
cross-over study between placebo, ginger extract and
Ibuprofen was undertaken to rank ginger extract in
comparison to the clinically most relevant alternatives.9Subjects and methods
SUBJECTS
After approval by the local ethical committee and obtain-
ing signed informed consent, six different investigators
included patients in the study from their practices (only
out-patients participated). Patients over 18 years of age
were eligible for the study. During the study period, very few
patients refused to enter the study. Criteria for exclusion
were a.o. rheumatoid arthritis, neurological disorders,
severe medical diseases, and dementia. Only patients
fluent in Danish participated. No injections in joints were
accepted within six months before the study.
All patients had complaints of clinical dysfunction
and pain due to osteoarthritis and radiologically verified
osteoarthritis (Kellgren grade 1–2; N=16, grade 3–4;
N=40) of the hip or knee with pain on movement of more
than 30 mm on a 100 mm VAS (mean 52 mm) at the first
visit (entry). Mean duration of osteoarthritis was 7.7 years
(range 1–30 years) and mean Lequesne index at entry was
11.8 (range 1–21.5).Received 25 January 1999; accepted 24 August 1999.
Address correspondence to: Professor Henning Bliddal, MD,
Dr Med Sci, Parker Institute, Frederiksberg Hospital, DK-2000
Copenhagen F, Denmark.
§Practices in rheumatology, Greater Copenhagen area. Contact
address: corresponding author.GINGER EXTRACT
An extract of selected Chinese ginger (Eurovita
Extract 33, EV.ext-33) with a standardized content of
10 H. Bliddal et al.: Ginger extracts in osteoarthritishydroxy-methoxy-phenyl compounds (HMP) was used.3
This extract was formulated in soft gelatine capsules which
shields the content of ginger.DESIGN
The study was conducted in a double-blind, double-
dummy, cross-over controlled design. At study entry, treat-
ment with analgesics and non-steroidal anti-inflammatory
drugs (NSAID) was discontinued for a one-week wash-
out period. The patients were then randomized to three
treatment periods of three weeks each, with either 170 mg
EV.ext-33 ginger extract, ibuprofen 400 mg or placebo
administered t.i.d. No further wash-out periods were used
between the three treatment periods. The patients were
randomized in blocks of six and furthermore within
these blocks there was a randomization according to the
six different sequences of the three types of treatment.
Each investigator included a minimum of six patients
consecutively.
As a rescue drug for pain during wash-out and through-
out the rest of the study, acetaminophen was delivered to
the patients by the investigators and used in a maximum
dosage of 3 grams daily. The study was conducted in
accordance with Good Clinical Practice (European Guide-
lines for GCP).MASKING
Both the Ibuprofen-tablet placebo and the EV.ext-33-
capsule placebo were indistinguishable from the originals,
and as long as it was intact, the capsule did not convey any
smell or taste of ginger. There was no difference in com-
pliance as judged from tablet and capsule consumption
during the three treatment periods.ASSESSMENT OF EFFICACY (OUTCOME MEASURES)
At study entry and at the end of each period, both
wash-out (henceforth, the values obtained at this visit are
called baseline-values) and treatment, the following items
were noted: a 100 mm VAS for pain assessment (primary
outcome variable), Lequesne-index for either hip or knee,4
and range of motion. The consumption of acetaminophen
was counted by patient and investigator at each visit.
Furthermore, the investigator’s preference of medication in
the different treatment periods was noted.
During each treatment period the patients filled in a diary
with a 4-point Likert pain scale each week.
Finally, the consumption of all trial medications was
counted at each visit by the investigator in the presence of
the patients.ASSESSMENT OF SAFETY
All adverse events, including changes in taste, were
noted throughout the study, either in the patients diary
and/or in the case record form at each visit. At entry and
after each treatment period blood samples were obtained
for measurement of haemoglobin.STATISTICS
The number of patients (60), eligible for calculation, was
calculated on the following assumptions: the SD of differ-ence between the patient’s VAS pain in two treatment
periods was assumed to be 12 mm (Bliddal et al. unpub-
lished), and the type 1 and type 2 errors were chosen at 5
and 10% respectively and the minimal relevant difference
between placebo and the most effective treatment groups
was chosen at 10 mm. Both Ibuprofen and ginger extracts
have a very short half-life, and the patient was only evalu-
ated after three weeks of therapy, which should minimize
carry-over effects from the previous treatment period. Fur-
thermore, a possible carry-over effect between the three
periods was balanced by the randomization of sequences
of therapies. In this design with a cross-over of three
treatment groups the effect was tested with a Friedman test
on the assumption that the ranking of efficiency was
Ibuprofen>ginger extract>placebo. The differences of the
individual treatments were estimated by Siegel-Castellan
test of multiple comparisons.5 Furthermore, non-parametric
tests as Kruskall-Wallis, Mann-Whitney and Page test for
trend were applied. Level of statistical significance was
chosen at 0.05.
All statistical analyses were performed by P.S. before the
breaking of the code.ResultsDEMOGRAPHICS AND COMPLIANCE
A total of 75 patients were evaluated for the study. Eight
patients were excluded during the wash-out period: four
because of intolerable increase in pain after withdrawal of
their regular NSAID and four due to withdrawal of consent.
Sixty-seven patients were randomized for the treatment
periods, and after secondary exclusion of 11 patients
(see ‘safety’ below) 56 patients were evaluable for the
whole study period. All the patients complied with the
prescheduled study-visits.
Of the 56 patients, 15 were men and 41 women. Twenty
had primarily osteoarthritis of the hip and 36 of the knee.
The age of the patients was mean 66 years (range 24–87
years) and the duration of osteoarthritis was mean 7.7
years (range 1–30 years). The weight was mean 78.3 kg
(range 53.5–120.0 kg).
Pain level at study entry was not significantly correlated
to the severity of the radiological changes. Most of the
patients had previously tried NSAID and at entry 31
patients were receiving NSAID treatment.EFFICACY
During the wash-out period VAS changed from entry
value median 51 mm (95% confidence limits 46–54) to
the baseline value 54 mm (95% confidence limits 47–63
Willcoxon: P<0.01).
The parameters of pain changed during therapy in all
periods, however, a highly significant ranking of efficacy
of the three treatment periods: Ibuprofen>ginger
extract>placebo was found for VAS (Friedman: 24.65,
P<0.0001), and the same trend was found for acetami-
nophen consumption (Friedman 11.7, P<0.01) as seen in
Fig. 1. Also, the Lequesne-index changed positively during
treatment with the same ranking (Fig. 2). The Siegel &
Castellan test for multiple comparisons showed a signifi-
cant difference in these tests between Ibuprofen and ginger
extract as well as Ibuprofen vs. placebo, but not between
ginger extract and placebo.
Osteoarthritis and Cartilage Vol. 8 No. 1 11The pain scores recorded in the patient diary could not
be assessed because the majority of the patients did not fill
in this form correctly.
In any of the three periods, no differences in range-of-
motion were noted. Investigator preference was in favour of
Ibuprofen (66%), while no differences were observed in
placebo or ginger extract (14 vs. 11%), and in 9%, all three
periods were considered equal.SAFETY
During the treatment period 11 patients were secondarily
excluded. Of these, four withdrew because of adverse
events: one patient was operated for intestinal strangu-
lation (placebo period), one had restless legs (placebo
period), one bad taste (ginger extract period), and one
nausea (Ibuprofen period). The other reasons were un-10
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Fig. 1. Changes on a 100-mm visual analogue scale (VAS) and the
total consumption of acetaminophen during three weeks treatment
with Ibuprofen, EV.ext-33 ginger extract (G) or placebo (P). Median
values and 95% confidence limits are shown. The ranking between
the three periods were tested by the Friedman test. For VAS:
Friedman test P<0.00001, Chi-square 24.65 (degree of freedom:
2); for Acetaminophen consumption: Friedman test P<0.01, Chi-
square 11.7 (degree of freedom: 2). Siegel-Castellan test for
multiple comparisons: Ibuprofen vs. EV.ext-33 ginger extract or
placebo P<0.001, EV.ext-33 ginger extract vs. Placebo n.s.10
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Fig. 2. The changes in Lequesne-index during three weeks treat-
ment with Ibuprofen, EV.ext-33 ginger extract (G) or placebo (P).
Median values and 95% confidence limits are shown. The ranking
between the three periods were tested by the Friedman test:
P<0.00005, Chi-square 20.76 (d.f. 2). Siegel-Castellan test for
multiple comparisons: Ibuprofen vs. EV.ext-33 ginger extract or
placebo P<0.001, EV.ext-33 ginger extract vs. Placebo n.s.Discussion
This study demonstrates a ranking of efficacy on pain
level and function in patients with osteoarthritis of the hip or
knee with Ibuprofen being more effective than ginger
extract (EV.ext-33) and placebo. The same ranking was
seen in the consumption of rescue medication, giving the
overall impression of a definite effect of Ibuprofen and a
small action of ginger extract. No difference between ginger
extract and placebo was demonstrated in a test for multiple
comparisons. However, prompted by a comment of a
reviewer, explorative statistical testing of the first period of
treatment (before cross-over) was performed and this
showed a better effect of both Ibuprofen and ginger extract
compared to that of placebo (Chi-square test, P<0.05). A
carry-over effect may blur possible effects of the later
treatment periods, and based on the present results,
caution should be observed in the interpretation of a
cross-over study of ginger extract.
During the three weeks of treatment no significant
adverse events were noted which could be ascribed to the
active substances.
Although the use of NSAIDs in osteoarthritis is highly
controversial6 the fact is that many doctors and patients do
favour these substances for both short and long-term use.
In our material two thirds of the patients were regular
NSAID users.
Ginger contains chemical substances with an anti-
inflammatory potential,7 and the effect might be attributed
to the actions of HMP. These are dual inhibitors of
cyclooxygenase and 5-lipoxygenase which makes the sub-
stances even more interesting in the field of rheumatol-
ogy.8,9 A suppressive effect of constituents of ginger has
been reported in arthritic rats.9 However, a long-term study
of the effects would require the development of a dummy
substance for the placebo-control, which has not been
possible to date.
The three week periods of therapy in this study might not
have been sufficient for all effects of ginger extract to be
discovered, and only one dose of ginger extract was
applied. Future studies might look into dose-response and
duration of therapy of EV.ext-33, if possible employing a
more potent extract of ginger.satisfying therapeutic effect (N=3), Lithium treatment
(N=1), and other, e.g. non-compliance (N=3).
In the 67 patients receiving test drugs, a total of 47
adverse events were registered in 34 patients. Two of the
adverse events could not be considered as side effects to
the trial medications (fall in snowy weather and acute low
back pain, both during placebo period). The other adverse
events were mainly gastrointestinal complaints (placebo
period N=8, ginger extract period N=9, and ibuprofen
period N=14). These complaints were characterized as
bad taste, which was only reported in ginger extract periods
(N=5), dyspepsia (placebo N=1, ginger extract N=1, Ibu-
profen N=7), changes in stools/intestinal trouble (placebo
N=6, ginger extract N=1, Ibuprofen N=4), or nausea
(placebo N=1, ginger extract N=1, Ibuprofen N=3). In
three patients allergic reactions were noted: skin allergy
(placebo period), periorbital oedema (Ibuprofen period),
and conjunctivitis (ginger extract period).
The haemoglobin values (pre-period minus end-period
value) were not affected to any clinically relevant extent by
any of the treatments.
12 H. Bliddal et al.: Ginger extracts in osteoarthritisIn the present study, the registered adverse events
during treatment with neither Ibuprofen nor EV.ext-33
reached statistical significance.
The ginger herb is extensively cultivated in the tropics
and, apart from the use as spice in cooking, it has been
recommended as medication for various illnesses during
several thousand years.2,11 Of the different constituents of
ginger, some seem to be responsible for the distinctive
taste,12 while other, different, compounds have specific
pharmacological effect e.g., inhibition of the prostaglandin
synthetase. The anti-inflammatory action of ginger has
been claimed to be the basis of a positive effect on
symptoms in rheumatic disorders.2
EV.ext-33 is highly purified with respect to HMP com-
pounds which have a sharp characteristic taste. Thus the
EV.ext-33 capsules should be swallowed and definitely not
chewed (personal experience). In our study, this effect was
described to the patients in detail before entry, and we
believe that the participants of the study have been honest
in their reports of taste of ginger. The study is as far as
possible blinded, but the possibility of bias due to taste
cannot be ruled out. However, as observed, the patients
reporting ginger taste did not differ from the rest of the
group in respect of pain score, Lequesne index or
consumption of paracetamol.
Doctors generally believe that ‘alternative’ medications
do not work at all1,13 and few keep an open mind towards
alternative medicine.14 In contrast, the ‘products of
nature’ seem to be very popular with RA patients, as two
thirds of sufferers turn to supplementary unorthodox
therapy each year.15 This inclination may be put to good
use if the patients change from NSAID to more harmless
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